BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhu K, Dai Z, Zhou J. Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy. Biomark Res. 2013;1:10. [PMID: 24252133 DOI: 10.1186/2050-7771-1-10] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Huang W, Li T, Yang W, Chai X, Chen K, Wei L, Duan S, Li B, Qin Y. Analysis of DNA methylation in plasma for monitoring hepatocarcinogenesis. Genet Test Mol Biomarkers 2015;19:295-302. [PMID: 25923138 DOI: 10.1089/gtmb.2014.0292] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
2 Chai Y, Zhao M. iTRAQ-Based Quantitative Proteomic Analysis of the Inhibitory Effects of Polysaccharides from Viscum coloratum (Kom.) Nakai on HepG2 Cells. Sci Rep 2017;7:4596. [PMID: 28676664 DOI: 10.1038/s41598-017-04417-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
3 Kim H, Sohn A, Yeo I, Yu SJ, Yoon JH, Kim Y. Clinical Assay for AFP-L3 by Using Multiple Reaction Monitoring-Mass Spectrometry for Diagnosing Hepatocellular Carcinoma. Clin Chem. 2018;64:1230-1238. [PMID: 29875214 DOI: 10.1373/clinchem.2018.289702] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
4 Birgani MT, Hajjari M, Shahrisa A, Khoshnevisan A, Shoja Z, Motahari P, Farhangi B. Long Non-Coding RNA SNHG6 as a Potential Biomarker for Hepatocellular Carcinoma. Pathol Oncol Res. 2017; Epub ahead of print. [PMID: 28508329 DOI: 10.1007/s12253-017-0241-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
5 Hasanzad M, Sarhangi N, Aghaei Meybodi HR, Nikfar S, Khatami F, Larijani B. Precision Medicine in Non Communicable Diseases. Int J Mol Cell Med 2019;8:1-18. [PMID: 32351905 DOI: 10.22088/IJMCM.BUMS.8.2.1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Cao W, Sharma M, Imam R, Yu J. Study on Diagnostic Values of Astrocyte Elevated Gene 1 (AEG-1) and Glypican 3 (GPC-3) in Hepatocellular Carcinoma. American Journal of Clinical Pathology 2019;152:647-55. [DOI: 10.1093/ajcp/aqz086] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
7 Sheu MJ, Hsieh MJ, Chou YE, Wang PH, Yeh CB, Yang SF, Lee HL, Liu YF. Effects of ADAMTS14 genetic polymorphism and cigarette smoking on the clinicopathologic development of hepatocellular carcinoma. PLoS One 2017;12:e0172506. [PMID: 28231306 DOI: 10.1371/journal.pone.0172506] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
8 Shaker MK, Abdel Fattah HI, Sabbour GS, Montasser IF, Abdelhakam SM, El Hadidy E, Yousry R, El Dorry AK. Annexin A2 as a biomarker for hepatocellular carcinoma in Egyptian patients. World J Hepatol 2017;9:469-76. [PMID: 28396717 DOI: 10.4254/wjh.v9.i9.469] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
9 Yang C, Yun Q, Sun H, Yang G, Liang T, Zhang C, Song J, Han J, Hou G. Non-invasive imaging of Toll-like receptor 5 expression using 131I-labeled mAb in the mice bearing H22 tumors. Oncol Lett 2014;7:1919-24. [PMID: 24932259 DOI: 10.3892/ol.2014.2025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
10 Furtado KS, de Oliveira Andrade F, Campos A, Rosim MP, Vargas-Mendez E, Henriques A, De Conti A, Scolastici C, Barbisan LF, Carvalho RF, Moreno FS. β-ionone modulates the expression of miRNAs and genes involved in the metastatic phenotype of microdissected persistent preneoplastic lesions in rats submitted to hepatocarcinogenesis. Mol Carcinog 2017;56:184-96. [PMID: 27061051 DOI: 10.1002/mc.22483] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
11 Toso C, Mazzaferro V, Bruix J, Freeman R, Mentha G, Majno P. Toward a better liver graft allocation that accounts for candidates with and without hepatocellular carcinoma. Am J Transplant. 2014;14:2221-2227. [PMID: 25220672 DOI: 10.1111/ajt.12923] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 6.1] [Reference Citation Analysis]
12 Chávez-López MG, Zúñiga-García V, Pérez-Carreón JI, Avalos-Fuentes A, Escobar Y, Camacho J. Eag1 channels as potential early-stage biomarkers of hepatocellular carcinoma. Biologics 2016;10:139-48. [PMID: 27703327 DOI: 10.2147/BTT.S87402] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
13 Yin J, Hou P, Wu Z, Wang T, Nie Y. Circulating miR-375 and miR-199a-3p as potential biomarkers for the diagnosis of hepatocellular carcinoma. Tumour Biol. 2015;36:4501-4507. [PMID: 25618599 DOI: 10.1007/s13277-015-3092-0] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 8.2] [Reference Citation Analysis]
14 Ghosh A, Ghosh A, Datta S, Dasgupta D, Das S, Ray S, Gupta S, Datta S, Chowdhury A, Chatterjee R. Hepatic miR-126 is a potential plasma biomarker for detection of hepatitis B virus infected hepatocellular carcinoma. Int J Cancer. 2016;138:2732-2744. [PMID: 26756996 DOI: 10.1002/ijc.29999] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
15 Dai W, Wu J, Zhang S, Shi B, Xu X, Wang D, Wang J. Genes directly regulated by NF-κB in human hepatocellular carcinoma HepG2. Int J Biochem Cell Biol 2017;89:157-70. [PMID: 28579529 DOI: 10.1016/j.biocel.2017.05.031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
16 Chauhan R, Lahiri N. Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma. Biomark Cancer. 2016;8:37-55. [PMID: 27398029 DOI: 10.4137/bic.s34413] [Cited by in Crossref: 26] [Cited by in F6Publishing: 42] [Article Influence: 5.2] [Reference Citation Analysis]
17 Deepak P, Siddalingam R, Kumar P, Anand S, Thakur S, Jagdish B, Jaiswal S. Gene based nanocarrier delivery for the treatment of hepatocellular carcinoma. Journal of Drug Delivery Science and Technology 2020;59:101837. [DOI: 10.1016/j.jddst.2020.101837] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Moreno-Fernandez ME, Giles DA, Stankiewicz TE, Sheridan R, Karns R, Cappelletti M, Lampe K, Mukherjee R, Sina C, Sallese A, Bridges JP, Hogan SP, Aronow BJ, Hoebe K, Divanovic S. Peroxisomal β-oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease. JCI Insight 2018;3:93626. [PMID: 29563328 DOI: 10.1172/jci.insight.93626] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
19 Attallah AM, El-Far M, Abdelrazek MA, Omran MM, Attallah AA, Elkhouly AA, Elkenawy HM, Farid K. Combined use of nuclear phosphoprotein c-Myc and cellular phosphoprotein p53 for hepatocellular carcinoma detection in high-risk chronic hepatitis C patients. Br J Biomed Sci 2017;74:170-5. [PMID: 28705056 DOI: 10.1080/09674845.2017.1334739] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
20 Feng PP, Qi YK, Li N, Fei HR. Scutebarbatine A induces cytotoxicity in hepatocellular carcinoma via activation of the MAPK and ER stress signaling pathways. J Biochem Mol Toxicol 2021;35:e22731. [PMID: 33512038 DOI: 10.1002/jbt.22731] [Reference Citation Analysis]
21 dela Rosa MAC, Chen W, Chen Y, Obena RP, Chang C, Capangpangan RY, Su T, Chen C, Chen P, Chen Y. One-Pot Two-Nanoprobe Assay Uncovers Targeted Glycoprotein Biosignature. Anal Chem 2017;89:3973-80. [DOI: 10.1021/acs.analchem.6b04396] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
22 Zhu K, Zhan H, Peng Y, Yang L, Gao Q, Jia H, Dai Z, Tang Z, Fan J, Zhou J. Plasma hsa_circ_0027089 is a diagnostic biomarker for hepatitis B virus-related hepatocellular carcinoma. Carcinogenesis 2020;41:296-302. [PMID: 31535687 DOI: 10.1093/carcin/bgz154] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 21.0] [Reference Citation Analysis]
23 Chang YY, Yen CJ, Chan SH, Chou YW, Lee YP, Bao CY, Huang CJ, Huang W. NEK2 Promotes Hepatoma Metastasis and Serves as Biomarker for High Recurrence Risk after Hepatic Resection. Ann Hepatol. 2018;17:843-856. [PMID: 30145571 DOI: 10.5604/01.3001.0012.3146] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
24 Maeda T, Kanzaki H, Chiba T, Ao J, Kanayama K, Maruta S, Kusakabe Y, Saito T, Kobayashi K, Kiyono S, Nakamura M, Ogasawara S, Suzuki E, Ooka Y, Nakamoto S, Nakagawa R, Muroyama R, Kanda T, Maruyama H, Kato N. Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma. BMC Cancer. 2019;19:1088. [PMID: 31718608 DOI: 10.1186/s12885-019-6322-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
25 Lu Z, Li X, Xu Y, Chen M, Chen W, Chen T, Tang Q, He Z. microRNA-17 functions as an oncogene by downregulating Smad3 expression in hepatocellular carcinoma. Cell Death Dis 2019;10:723. [PMID: 31558704 DOI: 10.1038/s41419-019-1960-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
26 Anwar SL, Lehmann U. MicroRNAs: Emerging Novel Clinical Biomarkers for Hepatocellular Carcinomas. J Clin Med. 2015;4:1631-1650. [PMID: 26295264 DOI: 10.3390/jcm4081631] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
27 Yu X, Zhang J, Yang R, Li C. Identification of Long Noncoding RNA Biomarkers for Hepatocellular Carcinoma Using Single-Sample Networks. Biomed Res Int 2020;2020:8579651. [PMID: 33299877 DOI: 10.1155/2020/8579651] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Zekri AR, Youssef AS, Bakr YM, Gabr RM, Ahmed OS, Elberry MH, Mayla AM, Abouelhoda M, Bahnassy AA. Early detection of hepatocellular carcinoma co-occurring with hepatitis C virus infection: A mathematical model. World J Gastroenterol 2016;22:4168-82. [PMID: 27122667 DOI: 10.3748/wjg.v22.i16.4168] [Reference Citation Analysis]
29 Fako V, Wang XW. The status of transarterial chemoembolization treatment in the era of precision oncology. Hepat Oncol 2017;4:55-63. [PMID: 28989699 DOI: 10.2217/hep-2017-0009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
30 Mezzalira S, De Mattia E, Guardascione M, Dalle Fratte C, Cecchin E, Toffoli G. Circulating-Free DNA Analysis in Hepatocellular Carcinoma: A Promising Strategy to Improve Patients' Management and Therapy Outcomes. Int J Mol Sci 2019;20:E5498. [PMID: 31694149 DOI: 10.3390/ijms20215498] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
31 Romano M, De Francesco F, Pirozzi G, Gringeri E, Boetto R, Di Domenico M, Zavan B, Ferraro GA, Cillo U. Expression of cancer stem cell biomarkers as a tool for a correct therapeutic approach to hepatocellular carcinoma. Oncoscience 2015;2:443-56. [PMID: 26097877 DOI: 10.18632/oncoscience.163] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
32 Likhitrattanapisal S, Tipanee J, Janvilisri T. Meta-analysis of gene expression profiles identifies differential biomarkers for hepatocellular carcinoma and cholangiocarcinoma. Tumour Biol 2016;37:12755-66. [PMID: 27448818 DOI: 10.1007/s13277-016-5186-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
33 Ziogas IA, Sioutas G, Mylonas KS, Tsoulfas G. Role of MicroRNA in the Diagnosis and Management of Hepatocellular Carcinoma. Microrna 2020;9:25-40. [PMID: 31218966 DOI: 10.2174/2211536608666190619155406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
34 Mathew S, Ali A, Abdel-hafiz H, Fatima K, Suhail M, Archunan G, Begum N, Jahangir S, Ilyas M, Chaudhary AG, Al Qahtani M, Mohamad Bazarah S, Qadri I. Biomarkers for virus-induced hepatocellular carcinoma (HCC). Infection, Genetics and Evolution 2014;26:327-39. [DOI: 10.1016/j.meegid.2014.06.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
35 Saad ZM, Fouad Y, Ali LH, Hassanin TM. Clinical Significance of Annexin A4 as a Biomarker in the Early Diagnosis of Hepatocellular Carcinoma. Asian Pac J Cancer Prev 2020;21:2661-5. [PMID: 32986366 DOI: 10.31557/APJCP.2020.21.9.2661] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Xia Y, Zhang Y, Shen M, Xu H, Li Z, He N. Golgi protein 73 and its diagnostic value in liver diseases. Cell Prolif 2019;52:e12538. [PMID: 30341783 DOI: 10.1111/cpr.12538] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
37 Junhom C, Weerapreeyakul N, Tanthanuch W, Thumanu K. Partial least squares regression and fourier transform infrared (FTIR) microspectroscopy for prediction of resistance in hepatocellular carcinoma HepG2 cells. Experimental Cell Research 2017;351:82-90. [DOI: 10.1016/j.yexcr.2016.12.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
38 Bhattacharji P, Moore W. Application of Real-Time 3D Navigation System in CT-Guided Percutaneous Interventional Procedures: A Feasibility Study. Radiol Res Pract 2017;2017:3151694. [PMID: 29181197 DOI: 10.1155/2017/3151694] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
39 Sacco R, Mismas V, Granito A, Musettini G, Masi G, Caparello C, Vivaldi C, Felder M, Bresci G, Fornaro L; Italian Liver Cancer (IT.LI.CA) group. Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA database. Int J Biol Markers 2015;30:e65-72. [PMID: 25450648 DOI: 10.5301/jbm.5000117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
40 Saad H, Zahran MA, Hendy O, Abdel-Samiee M, Bedair HM, Abdelsameea E. Matrix Metalloproteinase-11 Gene Polymorphisms as a Risk for Hepatocellular Carcinoma Development in Egyptian Patients. Asian Pac J Cancer Prev 2020;21:3725-34. [PMID: 33369474 DOI: 10.31557/APJCP.2020.21.12.3725] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Zhang YL, Zhang YC, Han W, Li YM, Wang GN, Yuan S, Wei FX, Wang JF, Jiang JJ, Zhang YW. Effect of GP73 silencing on proliferation and apoptosis in hepatocellular cancer. World J Gastroenterol. 2014;20:11287-11296. [PMID: 25170213 DOI: 10.3748/wjg.v20.i32.11287] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]